Abstract
MPC-1304 ((±)-methyl 2-oxopropyl 1,4-dihydro 2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate, CAS 86780-90-7), a new calcium antagonist, was orally administered to 10 outpatients with mild essential hypertension. It was observed that MPC-1304 inhibited elevations of blood pressure both at rest and under exercise loading without any adverse hemodynamie effects. The findings obtained indicated that MPC-1304 would be clinically useful in the treatment of hypertensive patients undergoing therapy while continuing normal everyday activities including physical exertion.
Original language | English (US) |
---|---|
Pages (from-to) | 1152-1156 |
Number of pages | 5 |
Journal | Arzneimittel-Forschung/Drug Research |
Volume | 43 |
Issue number | 11 |
State | Published - Jan 1 1993 |
Keywords
- (±)-methyl 2-oxopropyl 1,4-dihydro 2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridine dicarboxylate
- CAS 86780-90-7
- MPC-1304
- antihypertensives
- hypertension, essential
ASJC Scopus subject areas
- Drug Discovery